“Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024” Report Highlights:
- Significance for Monoclonal Antibodies for Cancer Treatment
- Global Cancer Monoclonal Antibodies Market Overview
- Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication
- Global Cancer Monoclonal Antibodies Pipeline: 697 mAb
- Marketed Cancer Monoclonal Antibodies: 60
- Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion
Download Report:
http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Monoclonal-Antibodies–Market-%26Clinical-Trial-Insight-2024
The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.
Report TOC
- Introduction to Monoclonal Antibodies
1.1 History of Development
1.2 Working of Monoclonal Antibodies
- Monoclonal Antibodies Classification
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins
- Monoclonal Antibodies Mechanisms
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes
- Significance for Monoclonal Antibodies for Cancer Treatment
- Global Cancer Monoclonal Antibodies Market Overview
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight
- Global Cancer Monoclonal Antibodies Market Future Outlook
- Global – Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
7.1 Phase-I/II
7.2 Phase-II
7.3 Phase-III
- Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight
8.1 Durvalumab (Imfinzi)
- Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration
- Marketed Blood Cancer Monoclonal Antibodies Clinical Insight
10.1 Daratumumab (DARZALEX)
10.2 Ofatumumab (Arzerra)
10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)
10.4 Blinatumomab (Blincyto)
10.5 Elotuzumab (Empliciti)
10.6 Mogamulizumab (Poteligeo)
10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
10.8 Brentuximab Vedotin (Adcetris)
10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)
10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)
10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
10.12 Rituximab Biosimilar (Rixathon & Riximyo)
10.13 Gemtuzumab Ozogamicin (Mylotarg)
10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)
10.16 Rituximab Biosimilar (Novex)
10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)
10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
10.19 Rituximab Biosimilar (Zytux)
10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
10.21 Rituximab Biosimilar (Maball)
10.22 Rituximab Biosimilar (Kikuzubam)
10.23 Rituximab Biosimilar (Mabtas)
- Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
11.8 Registered
- Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
12.1 Trastuzumab Subcutaneous (Herceptin SC)
12.2 Pertuzumab (Omnitarg & Perjeta)
12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
12.4 Trastuzumab Emtansine (Kadcyla)
12.5 Trastuzumab Biosimilar (Vivitra)
- Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
13.1 Phase-III
- Marketed Bone Cancer Monoclonal Antibodies Clinical Insight
14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)
- Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
15.1 Preclinical
15.2 Phase-I/II
15.3 Phase-III
15.4 Registered
- Marketed Brain Cancer Monoclonal Antibodies Clinical Insight
16.1 Dinutuximab (Unituxin)
- Global – Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
17.1 Phase-I/II
- Global – Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase
18.1 Unknown
18.2 Preclinical
18.3 Phase-I
- Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-III
- Global – Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
20.1 Phase-II
- Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
21.1 Preclinical
21.2 Phase-II
21.3 Phase-III
- Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
22.1 Research
22.2 Preclinical
22.3 Phase-I
22.4 Phase-I/II
22.5 Phase-II/III
22.6 Phase-III
22.7 Preregistration
- Marketed Skin Cancer Monoclonal Antibodies Clinical Insight
23.1 Avelumab (BAVENCIO)
23.2 Olaratumab (Lartruvo)
- Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
24.1 Preclinical
24.2 Phase-I/II
24.3 Phase-II
24.4 Phase-III
24.5 Preregistration
- Marketed Stomach Cancer Monoclonal Antibodies Clinical
25.1 Bevacizumab Biosimilar (Bevax)
25.2 Cetuximab Biosimilar – CinnaGen
25.3 Bevacizumab Biosimilar (Cizumab)
- Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
26.1 Research
26.2 Clinical
26.3 Phase-I
26.4 Phase-I/II
26.5 Phase-II
26.6 Phase-II/III
26.7 Phase-III
26.8 Preregistration
26.9 Registered
- Marketed Lung Cancer Monoclonal Antibodies Clinical Insight
27.1 Necitumumab (Portrazza)
27.2 Iodine I 131 Derlotuximab Biotin (Cotara)
27.3 Bevacizumab Biosimilar (Bryxta)
27.4 Racotumomab (Vaxira)
27.5 Racotumomab (Vaxira)
27.6 Tc 99m Nofetumomab Merpentan (VerLuma)
- Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
28.1 Research
28.2 Preclinical
28.3 Phase-I
28.4 Phase-I/II
28.5 Phase-II
- Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
29.1 Preclinical
29.2 Phase-I
29.3 Phase-I/II
29.4 Phase-II
- Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight
30.1 Gemcitabine elaidate companion diagnostic – Ventana Medical Systems/Clovis Oncology
- Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
31.1 Preclinical
31.2 Phase-II
- Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase
32.1 Unknown
32.2 Research
32.3 Preclinical
32.4 Clinical
32.5 Phase-I
32.6 Phase-I/II
32.7 Phase-II
32.8 Phase-II/III
32.9 Phase-III
32.10 Registered
- Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight
33.1 Cetuximab (Erbitux)
33.2 Nivolumab (Opdivo)
33.3 Bevacizumab (Avastin)
33.4 Trastuzumab (Herceptin)
33.5 Atezolizumab (TECENTRIQ)
33.6 Rituximab (MabThera & Rituxan)
33.7 Ramucirumab (Cyramza, Sairamza & Silamza)
33.8 Trastuzumab Biosimilar (Herzuma)
33.9 Pembrolizumab (Keytruda)
33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
33.11 Ipilimumab (Yervoy)
33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.14 Bevacizumab Biosimilar (KRABEVA)
33.15 Bevacizumab Biosimilar (Mvasi)
33.16 Trastuzumab Biosimilar (AryoTrust)
33.17 Satumomab (OncoScint CR/OV)
- Competitive Landscape
34.1 Abbvie
34.2 Amgen
34.3 Bayer HealthCare
34.4 Biogen Idec
34.5 Eli Lilly
34.6 Genmab
34.7 Gilead Sciences
34.8 GlaxoSmithKline
34.9 Novartis
34.10 Pfizer
34.11 Roche
34.12 Seattle Genetics
